TAK-593 is a novel, orally bioavailable and potent small-molecule receptor of VEGFR and PDGFR with IC50s of 3.2, 0.95, 1.1, 4.3 and 13 nM for VEGFR1, VEGFR2, VEGFR3, PDFGRα and PDFGRβ, respectively.

SU-4312, formerly known as DMBI, is a potent and selective inhibitor of VEGFR and PDGFR tyrosine kinases (IC50 are 0.8 and 19.4 μM respectively).

Sennoside B is a naturally occuring anthraquinone glycoside compound isolated from Puffer fish, salamanders, frogs foot spot et al.,

Anlotinib (formerly known as AL3818) is a novel and potent multi-kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFRα/β, c-Kit, and Ret.

Masitinib (formerly also known as AB1010) is a novel, potent, orally bioavailable, selective and multi-targeted inhibitor for Kit and PDGFRα/β with IC50 of 200 nM and 540 nM/800 nM, it shows weak inhibition to ABL and c-Fms.

Tyrphostin AG 1296 (AG-1296) is a novel, potent, selective and ATP-competitive inhibitor of PDGFR with potential antitumor activity.

CP-673451 (CP673451) is a novel, potent, selective and ATP-competitive inhibitor of PDGFR(α/β) with potential antitumor activity.

Toceranib phosphate (formerly known as PHA291639; SU11654), phosphate salt of Toceranib, is a novel and potent receptor tyrosine kinase (RTK) inhibitor with antineoplastic/anticancer activities.

Trapidil AR-12008) is a potent coronary vasodilator agent that is used as an antiplatelet drug with specific platelet-derived growth factor.

Crenolanib (formerly also known as CP868596; RO-002; ARO-002), a benzimidazole compound, is an orally bioavailable and selective small molecule inhibitor of platelet-derived growth factor receptor (PDGFRα/β) with potential anticancer activity.